本帖最后由 老马 于 2012-1-13 21:20 编辑
& z5 Q# S5 }7 Y. Y2 _* y0 u/ H9 e1 F' n& c; ~8 g4 z
爱必妥和阿瓦斯丁的比较8 q" a9 X4 D9 F! f% N7 x7 L
+ l" Z7 P( w" b [; r Shttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 U7 M* ^ v9 V: R, F" k
+ {; k. U' d0 M, Y$ |" {
4 t( l+ G: @3 F3 w o' o! A* ]http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ q# `& w, Z2 E0 j- k# a0 `$ W. m
==================================================
/ u8 q* w+ r) F! K$ ZOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) f* Y1 D3 @" U/ x% ^* oPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 W: [& c/ ^: x' L# U# s8 z- PResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 z2 ^5 K% f% a' l
|